Trials / Completed
CompletedNCT02534480
Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose)
A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally-administered NGP 555 in Healthy Young Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- NeuroGenetic Pharmaceuticals Inc · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
NGP 555 is a small molecule preventative therapy aimed at reducing Alzheimer's disease amyloid buildup by targeting Abeta 42 production.
Detailed description
NGP 555 is a gamma-secretase modulator with a selective mechanism to reduce Abeta 42 while raising shorter Abeta forms such as Abeta 37 and 38. NGP 555 is being developed as a preventative disease modifying therapy for Alzheimer's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NGP 555 | Gamma-secretase modulator for the treatment of Alzheimer's disease |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2015-10-01
- Completion
- 2015-11-01
- First posted
- 2015-08-27
- Last updated
- 2016-01-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02534480. Inclusion in this directory is not an endorsement.